Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents.

Fizazi, K; Gillessen, S

Fizazi, K; Gillessen, S.

Affiliation

Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
Gillessen S; Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.

Ann Oncol ; 34(6): 557-563, 2023 06.

Article in En | MEDLINE | ID: mdl-36958590

Subject(s)

Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Male; Humans; Prostatic Neoplasms/drug therapy; Treatment Outcome; Prostatic Neoplasms, Castration-Resistant/drug therapy; Prostate-Specific Antigen

Key words

Clinical Practice Guideline; Lu-PSMA; abirateroneprednisone; cabazitaxel; darolutamide; prostate cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant Type of study: Guideline Limits: Humans / Male Language: En Journal: Ann Oncol Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google